ERBB2 and non-small cell lung carcinoma: In an ongoing phase 1 trial, trastuzumab deruxtecan (6.4 mg/kg) had a confirmed ORR of 58.8% (10/17) in HER2-expressing or mutated NSCLC, and 72.7% (8/11) in HER2-mutated NSCLC, with a manageable safety profile.77